Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Head and Neck Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 77 articles:
HTML format
Text format



Single Articles


    May 2018
  1. BHATIA S, Sharma J, Bukkapatnam S, Oweida A, et al
    Inhibition of EphB4-ephrin-B2 signaling enhances response to Cetuximab-radiation therapy in head and neck cancers.
    Clin Cancer Res. 2018 May 30. pii: 1078-0432.CCR-18-0327.
    PubMed     Text format     Abstract available


  2. TAN YS, Sansanaphongpricha K, Xie Y, Donnelly CR, et al
    Mitigating SOX2-potentiated immune escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing nanosatellite vaccine.
    Clin Cancer Res. 2018 May 16. pii: 1078-0432.CCR-17-2807.
    PubMed     Text format     Abstract available


    April 2018
  3. LIU Z, McMichael EL, Shayan G, Li J, et al
    Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients.
    Clin Cancer Res. 2018 Apr 30. pii: 1078-0432.CCR-17-1350.
    PubMed     Text format     Abstract available


    March 2018
  4. XU C, Nikolova O, Basom R, Mitchell RM, et al
    Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1339.
    PubMed     Text format     Abstract available


  5. MENDEZ E, Rodriguez CP, Kao M, Raju SC, et al
    A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-3796.
    PubMed     Text format     Abstract available


  6. ZHAO X, Brusadelli MG, Sauter SL, Butsch Kovacic M, et al
    Lipidomic profiling links the Fanconi anemia pathway to glycosphingolipid metabolism in head and neck cancer cells.
    Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-3686.
    PubMed     Text format     Abstract available


    February 2018
  7. SOULIERES D, Lictira L, Mesia R, Remenar E, et al
    Molecular Alterations and Buparlisib Efficacy in Patients With Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis From BERIL-1.
    Clin Cancer Res. 2018 Feb 28. pii: 1078-0432.CCR-17-2644.
    PubMed     Text format     Abstract available


  8. CHEN YP, Tang LL, Yang Q, Poh SS, et al
    Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials.
    Clin Cancer Res. 2018 Feb 5. pii: 1078-0432.CCR-17-2656.
    PubMed     Text format     Abstract available


    January 2018
  9. HUI EP, Ma BBY, Loong H, Mo F, et al
    Efficacy, safety and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase 2 correlative study.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1667.
    PubMed     Text format     Abstract available


  10. COGHILL AE, Pfeiffer RM, Proietti C, Hsu WL, et al
    Identification of a novel, EBV-based antibody risk stratification signature for early detection of nasopharyngeal carcinoma in Taiwan.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1929.
    PubMed     Text format     Abstract available


  11. SCHMIDT S, Linge A, Zwanenburg A, Leger S, et al
    Development and validation of a gene signature for patients with head and neck squamous cell carcinomas treated by postoperative radio(chemo)therapy.
    Clin Cancer Res. 2018 Jan 3. pii: 1078-0432.CCR-17-2345.
    PubMed     Text format     Abstract available


    December 2017
  12. THEODORAKI MN, Yerneni S, Hoffmann TK, Gooding WE, et al
    Clinical significance of PD-L1+ exosomes in plasma of Head and Neck Cancer patients.
    Clin Cancer Res. 2017 Dec 12. pii: 1078-0432.CCR-17-2664.
    PubMed     Text format     Abstract available


  13. CHUNG MK, Jung YH, Lee JK, Cho SY, et al
    CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma Through the Upregulation of Slug.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-0866.
    PubMed     Text format     Abstract available


    November 2017
  14. KRAFT IL, Akshintala S, Zhu YJ, Lei H, et al
    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Clin Cancer Res. 2017 Nov 29. pii: 1078-0432.CCR-17-2101.
    PubMed     Text format     Abstract available


  15. WANG X, Beitler JJ, Huang W, Chen G, et al
    Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-0345.
    PubMed     Text format     Abstract available


  16. FUKUSUMI T, Guo T, Sakai A, Ando M, et al
    The NOTCH4-HEY1 pathway induces epithelial mesenchymal transition in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2017 Nov 16. pii: clincanres.1366.2017.
    PubMed     Text format     Abstract available


  17. ZHONG Q, Liu Z, Lin ZR, Hu ZD, et al
    The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2017 Nov 13. pii: clincanres.0352.2016.
    PubMed     Text format     Abstract available


  18. LIU X, Kumar M, Yang L, Molkentine DP, et al
    BAP1 is a novel target in HPV negative head and neck cancer.
    Clin Cancer Res. 2017 Nov 7. pii: clincanres.1573.2017.
    PubMed     Text format     Abstract available


  19. LIN C, Zhang N, Wang Y, Wang Y, et al
    Functional Role of A Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis.
    Clin Cancer Res. 2017 Nov 3. pii: clincanres.1851.2017.
    PubMed     Text format     Abstract available


    October 2017
  20. SHAYAN G, Kansy BA, Gibson SP, Srivastava RM, et al
    A Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.0357.2017.
    PubMed     Text format     Abstract available


  21. NIEHR F, Eder T, Pilz T, Konschak R, et al
    Multilayered omics-based analysis of a head and neck cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2410.2017.
    PubMed     Text format     Abstract available


  22. YANG Q, Zhang MX, Zou X, Liu YP, et al
    A prognostic bio-model based on SQSTM1 and N stage identifies nasopharyngeal carcinoma patients at high risk of metastasis for additional induction chemotherapy.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1963.2017.
    PubMed     Text format     Abstract available


    September 2017
  23. WOOD O, Clarke J, Woo J, Mirza AH, et al
    Head and neck squamous cell carcinomas are characterized by a stable immune signature within the primary tumor over time.
    Clin Cancer Res. 2017 Sep 26. pii: clincanres.0373.2017.
    PubMed     Text format     Abstract available


  24. BIKTASOVA AK, Hajek M, Sewell AB, Gary CS, et al
    Demethylation therapy as a targeted treatment for human papilloma virus-associated head and neck cancer.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1438.2017.
    PubMed     Text format     Abstract available


    July 2017
  25. WHITESIDE TL
    Head and Neck Carcinoma Immunotherapy: Facts and Hopes.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1261.2017.
    PubMed     Text format     Abstract available


  26. MELL LK, Brumund KT, Daniels GA, Advani SJ, et al
    PHASE I TRIAL OF INTRAVENOUS ONCOLYTIC VACCINIA VIRUS (GL-ONC1) WITH CISPLATIN AND RADIOTHERAPY IN PATIENTS WITH LOCOREGIONALLY ADVANCED HEAD AND NECK CARCINOMA.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3232.2016.
    PubMed     Text format     Abstract available


    June 2017
  27. LU G, Little JV, Wang X, Zhang H, et al
    Detection of Head and Neck Cancer in Surgical Specimens Using Quantitative Hyperspectral Imaging.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.0906.2017.
    PubMed     Text format     Abstract available


    May 2017
  28. OZAWA H, Ranaweera R, Izumchenko E, Makarev E, et al
    SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells.
    Clin Cancer Res. 2017 May 18. pii: clincanres.1686.2016.
    PubMed     Text format     Abstract available


  29. CHOW LQM, Morishima C, Eaton KD, Baik CS, et al
    Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
    Clin Cancer Res. 2017;23:2442-2450.
    PubMed     Text format     Abstract available


  30. SKINNER HD, Giri U, Yang LP, Kumar M, et al
    Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
    Clin Cancer Res. 2017 May 5. doi: 10.1158/1078-0432.CCR-16-2586.
    PubMed     Text format     Abstract available


  31. TZENG HT, Tsai CH, Yen YT, Cheng HC, et al
    Dysregulation of Rab37-Mediated Cross-talk between Cancer Cells and Endothelial Cells via Thrombospondin-1 Promotes Tumor Neovasculature and Metastasis.
    Clin Cancer Res. 2017;23:2335-2345.
    PubMed     Text format     Abstract available


  32. UPPALURI R, Winkler AE, Lin T, Law JH, et al
    Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.
    Clin Cancer Res. 2017;23:2186-2194.
    PubMed     Text format     Abstract available


    April 2017
  33. ROSENTHAL E, Moore L, Tipirneni K, de Boer E, et al
    Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.2968.2016.
    PubMed     Text format     Abstract available


  34. SALOURA V, Fatima A, Zewde M, Kiyotani K, et al
    Characterization of the tumor T-cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2017 Apr 25. pii: clincanres.0103.2017.
    PubMed     Text format     Abstract available


  35. LUDWIG S, Floros T, Theodoraki MN, Hong CS, et al
    Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.2819.2016.
    PubMed     Text format     Abstract available


    March 2017
  36. DERAKHSHAN A, Chen Z, Van Waes C
    Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.
    Clin Cancer Res. 2017;23:1379-1387.
    PubMed     Text format     Abstract available


  37. ZHANG S, Zhang B, Tian J, Dong D, et al
    Radiomics features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.2910.2016.
    PubMed     Text format     Abstract available


    February 2017
  38. HSU DS, Hwang WL, Yuh CH, Chu CH, et al
    Lymphotoxin-beta interacts with methylated EGFR to mediate acquired resistance to cetuximab in head and neck cancer.
    Clin Cancer Res. 2017 Feb 14. pii: clincanres.1955.2016.
    PubMed     Text format     Abstract available


    January 2017
  39. KANG H, Tan M, Bishop JA, Jones S, et al
    Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma.
    Clin Cancer Res. 2017;23:283-288.
    PubMed     Text format     Abstract available


    December 2016
  40. BRAND TM, Hartmann S, Bhola NE, Peyser ND, et al
    Human papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2203.2016.
    PubMed     Text format     Abstract available


  41. MUHAMMAD N, Bhattacharya S, Steele R, Phillips NJ, et al
    Involvement of c-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Dec 13. pii: clincanres.2811.2016.
    PubMed     Text format     Abstract available


    October 2016
  42. KERK S, Finkel K, Pearson AT, Warner K, et al
    5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Oct 25. pii: clincanres.1834.2016.
    PubMed     Text format     Abstract available


  43. YAMAMURA K, Baba Y, Nakagawa S, Mima K, et al
    Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  44. RAUE F, Frank-Raue K
    Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Clin Cancer Res. 2016;22:5012-5021.
    PubMed     Text format     Abstract available


    September 2016
  45. MANCIKOVA V, Montero-Conde C, Perales-Paton J, Fernandez AF, et al
    Multilayer OMIC data in medullary thyroid carcinoma identifies the STAT3 pathway as a potential therapeutic target in RETM918T tumors.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.0947.2016.
    PubMed     Text format     Abstract available


    August 2016
  46. SRIVASTAVA RM, Trivedi S, Concha-Benavente F, Gibson SP, et al
    CD137 stimulation enhances cetuximab induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and neck cancer patients.
    Clin Cancer Res. 2016 Aug 5. pii: clincanres.0879.2016.
    PubMed     Text format     Abstract available


    July 2016
  47. ZHU X, Enomoto K, Zhao L, Zhu YJ, et al
    Bromodomain and extraterminal protein inhibitor JQ1 suppresses thyroid tumor growth in a mouse model.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0914.2016.
    PubMed     Text format     Abstract available


  48. ZHANG JX, Chen ZH, Xu Y, Chen JW, et al
    Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem-cell-like Phenotype via Dysregulation of PITX2.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0414.2016.
    PubMed     Text format     Abstract available


  49. HARTMANN S, Bhola NE, Grandis JR
    HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
    Clin Cancer Res. 2016 Jul 1. pii: clincanres.0951.2016.
    PubMed     Text format     Abstract available


    June 2016

  50. Correction: Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients.
    Clin Cancer Res. 2016;22:3118.
    PubMed     Text format    


  51. ABDULGHANI J, Gokare P, Gallant JN, Dicker DT, et al
    Sorafenib and quinacrine target anti-apoptotic protein Mcl-1: a poor prognostic marker in anaplastic thyroid cancer (ATC).
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.2792.2015.
    PubMed     Text format     Abstract available


    May 2016
  52. TRIVEDI S, Srivastava RM, Concha-Benavente F, Ferrone S, et al
    Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor cellular immunity in head and neck cancer patients.
    Clin Cancer Res. 2016 May 23. pii: clincanres.2971.2015.
    PubMed     Text format     Abstract available


    April 2016
  53. CHAU NG, Hammerman PS
    Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon.
    Clin Cancer Res. 2016 Apr 29. pii: clincanres.0582.2016.
    PubMed     Text format     Abstract available


  54. ZHANG Y, Koneva LA, Virani S, Arthur AE, et al
    Subtypes of HPV-positive head and neck cancers are associated with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway signatures.
    Clin Cancer Res. 2016 Apr 18. pii: clincanres.0323.2016.
    PubMed     Text format     Abstract available


  55. ZUMSTEG ZS, Morse N, Krigsfeld G, Gupta G, et al
    Taselisib (GDC-0032), a Potent beta-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Clin Cancer Res. 2016;22:2009-19.
    PubMed     Text format     Abstract available


  56. SKINNER HD, Giri U, Yang L, Woo SH, et al
    Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV negative head and neck cancer.
    Clin Cancer Res. 2016 Apr 1. pii: clincanres.2785.2015.
    PubMed     Text format     Abstract available


  57. GRANDIS J
    HER2 and HER3 in HPV+ and HPV- HNSCC--Response.
    Clin Cancer Res. 2016;22:1826.
    PubMed     Text format    


  58. MACHIELS JP, Galot R, Schmitz S
    HER2 and HER3 in HPV+ and HPV- HNSCC--Letter.
    Clin Cancer Res. 2016;22:1825.
    PubMed     Text format    


    March 2016
  59. CHEN P, Hu T, Liang Y, Li P, et al
    Neddylation Inhibition Activates the Extrinsic Apoptosis Pathway through ATF4-CHOP-DR5 Axis in Human Esophageal Cancer Cells.
    Clin Cancer Res. 2016 Mar 16. pii: clincanres.2254.2015.
    PubMed     Text format     Abstract available


  60. KOOLE K, Brunen D, van Kempen PM, Noorlag R, et al
    FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.1874.2015.
    PubMed     Text format     Abstract available


    February 2016
  61. COGHILL AE, Bu W, Nguyen H, Hsu WL, et al
    High levels of antibody that neutralize B-cell infection of Epstein-Barr virus and that bind EBV gp350 are associated with a lower risk of nasopharyngeal carcinoma.
    Clin Cancer Res. 2016 Feb 26. pii: clincanres.2299.2015.
    PubMed     Text format     Abstract available


  62. LEE Y, Shin JH, Longmire M, Wang H, et al
    CD44+ cells in head and neck squamous cell carcinoma suppress T cell-mediated immunity by selective constitutive and inducible expression of PD-L1.
    Clin Cancer Res. 2016 Feb 10. pii: clincanres.2665.2015.
    PubMed     Text format     Abstract available


  63. YU XM, Jaskula-Sztul R, Georgen MR, Aburjania Z, et al
    Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression.
    Clin Cancer Res. 2016 Feb 4. pii: clincanres.1749.2015.
    PubMed     Text format     Abstract available


  64. MITANI Y, Liu B, Rao PH, Borra VJ, et al
    Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
    Clin Cancer Res. 2016;22:725-33.
    PubMed     Text format     Abstract available


  65. VASSILAKOPOULOU M, Avgeris M, Velcheti V, Kotoula V, et al
    Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2016;22:704-13.
    PubMed     Text format     Abstract available


    January 2016
  66. CHAU NG, Li YY, Jo VY, Rabinowits G, et al
    Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.2314.2015.
    PubMed     Text format     Abstract available


    December 2015
  67. ROTHENBERG SM, Daniels GH, Wirth LJ
    Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.
    Clin Cancer Res. 2015;21:5640-5641.
    PubMed     Text format    


  68. HUILLARD O, Tenenbaum F, Clerc J, Goldwasser F, et al
    Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Letter.
    Clin Cancer Res. 2015;21:5639.
    PubMed     Text format    


    November 2015
  69. ROMICK-ROSENDALE LE, Hoskins EE, Privette Vinnedge LM, Foglesong GD, et al
    Defects in the Fanconi anemia pathway in head and neck cancer cells stimulate tumor cell invasion through DNA-PK and Rac1 signaling.
    Clin Cancer Res. 2015 Nov 24. pii: clincanres.2209.2015.
    PubMed     Text format     Abstract available


    October 2015
  70. SWIERNIAK M, Wojcicka A, Czetwertynska M, Dlugosinska J, et al
    Association Between GWAS-derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1746.2015.
    PubMed     Text format     Abstract available


    August 2015
  71. NAIR A, Lemery SJ, Yang J, Marathe A, et al
    FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Clin Cancer Res. 2015 Aug 31. pii: clincanres.1377.2015.
    PubMed     Text format     Abstract available


  72. SCHLUMBERGER M, Jarzab B, Cabanillas ME, Robinson BG, et al
    A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC).
    Clin Cancer Res. 2015 Aug 26. pii: clincanres.1127.2015.
    PubMed     Text format     Abstract available


    June 2015
  73. CASAK SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, et al
    FDA Approval Summary: Ramucirumab for Gastric Cancer.
    Clin Cancer Res. 2015 Jun 5. pii: clincanres.0600.2015.
    PubMed     Text format     Abstract available


  74. JURIC D, Dienstmann R, Cervantes A, Hidalgo M, et al
    Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
    Clin Cancer Res. 2015;21:2462-70.
    PubMed     Text format     Abstract available


    May 2015
  75. MEHTA A, Zhang L, Boufraqech M, Liu-Chittenden Y, et al
    Inhibition of survivin with YM155 induces durable tumor response in anaplastic thyroid cancer.
    Clin Cancer Res. 2015 May 5. pii: clincanres.3251.2014.
    PubMed     Text format     Abstract available


    April 2015
  76. MACDONALD AJ, Johns N, Stephens N, Greig C, et al
    Habitual Myofibrillar Protein Synthesis Is Normal in Patients with Upper GI Cancer Cachexia.
    Clin Cancer Res. 2015;21:1734-40.
    PubMed     Text format     Abstract available


    December 2014
  77. ROTHENBERG SM, McFadden DG, Palmer EL, Daniels GH, et al
    Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
    Clin Cancer Res. 2014 Dec 30. pii: clincanres.2915.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: